DNA Methylation Profiles in Primary Cutaneous Melanomas Are Associated with Clinically Significant Pathologic Features

Overview

Journal Pigment Cell Melanoma Res

Date 2014 Jul 3

PMID 24986547

Citations 11

Authors

Nancy E Thomas

Nathaniel A Slater

Sharon N Edmiston

Xin Zhou

Pei-Fen Kuan

Pamela A Groben

Craig C Carson

Honglin Hao

Eloise Parrish

Stergios J Moschos

Marianne Berwick

David W Ollila

Kathleen Conway

Affiliations

Soon will be listed here.

Abstract

DNA methylation studies have elucidated a methylation signature distinguishing primary melanomas from benign nevi and provided new insights about genes that may be important in melanoma development. However, it is unclear whether methylation differences among primary melanomas are related to tumor pathologic features with known clinical significance. We utilized the Illumina GoldenGate Cancer Panel array to investigate the methylation profiles of 47 primary cutaneous melanomas. Arraywide methylation patterns revealed a positive association of methylation with Breslow thickness and mutated BRAF, a negative association with mitotic rate, and a weak association with ulceration. Hierarchical clustering on CpG sites exhibiting the most variable methylation (n = 235) divided the melanoma samples into three clusters, including a highly methylated cluster that was positively associated with Breslow thickness and an intermediately methylated cluster associated with Breslow thickness and mitotic rate. Our findings provide support for the existence of methylation-defined subsets in melanomas with increased methylation associated with Breslow thickness.

Citing Articles

Integrative analysis of DNA methylation and gene expression in skin cutaneous melanoma by bioinformatic approaches.

Zhang L, Peng Y, Huang S, Zhong L Arch Dermatol Res. 2025; 317(1):545.

PMID: 40067504 PMC: 11897118. DOI: 10.1007/s00403-025-03863-2.

DNA Methylation Classes of Stage II and III Primary Melanomas and Their Clinical and Prognostic Significance.

Conway K, Edmiston S, Vondras A, Reiner A, Corcoran D, Shen R JCO Precis Oncol. 2024; 8:e2400375.

PMID: 39509669 PMC: 11737429. DOI: 10.1200/PO-24-00375.

Rapidly Evolving Pre- and Post-surgical Systemic Treatment of Melanoma.

Augustin R, Luke J Am J Clin Dermatol. 2024; 25(3):421-434.

PMID: 38409643 PMC: 11552441. DOI: 10.1007/s40257-024-00852-5.

Higher methylation subtype of malignant melanoma and its correlation with thicker progression and worse prognosis.

Yamamoto Y, Matsusaka K, Fukuyo M, Rahmutulla B, Matsue H, Kaneda A Cancer Med. 2020; 9(19):7194-7204.

PMID: 32406600 PMC: 7541157. DOI: 10.1002/cam4.3127.

Aberrant DNA Methylation Predicts Melanoma-Specific Survival in Patients with Acral Melanoma.

Pradhan D, Jour G, Milton D, Vasudevaraja V, Tetzlaff M, Nagarajan P Cancers (Basel). 2020; 11(12).

PMID: 31888295 PMC: 6966546. DOI: 10.3390/cancers11122031.

References

Thomas N, Edmiston S, Alexander A, Millikan R, Groben P, Hao H . Number of nevi and early-life ambient UV exposure are associated with BRAF-mutant melanoma. Cancer Epidemiol Biomarkers Prev. 2007; 16(5):991-7. DOI: 10.1158/1055-9965.EPI-06-1038. View

Sigalotti L, Covre A, Fratta E, Parisi G, Sonego P, Colizzi F . Whole genome methylation profiles as independent markers of survival in stage IIIC melanoma patients. J Transl Med. 2012; 10:185. PMC: 3539917. DOI: 10.1186/1479-5876-10-185. View

Rakosy Z, Ecsedi S, Toth R, Vizkeleti L, Hernandez-Vargas H, Herandez-Vargas H . Integrative genomics identifies gene signature associated with melanoma ulceration. PLoS One. 2013; 8(1):e54958. PMC: 3559846. DOI: 10.1371/journal.pone.0054958. View

van den Hurk K, Niessen H, Veeck J, van den Oord J, van Steensel M, Zur Hausen A . Genetics and epigenetics of cutaneous malignant melanoma: a concert out of tune. Biochim Biophys Acta. 2012; 1826(1):89-102. DOI: 10.1016/j.bbcan.2012.03.011. View

Tanemura A, Terando A, Sim M, van Hoesel A, de Maat M, Morton D . CpG island methylator phenotype predicts progression of malignant melanoma. Clin Cancer Res. 2009; 15(5):1801-7. PMC: 2703821. DOI: 10.1158/1078-0432.CCR-08-1361. View

Koga Y, Pelizzola M, Cheng E, Krauthammer M, Sznol M, Ariyan S . Genome-wide screen of promoter methylation identifies novel markers in melanoma. Genome Res. 2009; 19(8):1462-70. PMC: 2720187. DOI: 10.1101/gr.091447.109. View

Gao L, Smit M, van den Oord J, Goeman J, Verdegaal E, van der Burg S . Genome-wide promoter methylation analysis identifies epigenetic silencing of MAPK13 in primary cutaneous melanoma. Pigment Cell Melanoma Res. 2013; 26(4):542-54. DOI: 10.1111/pcmr.12096. View

Thomas N, Alexander A, Edmiston S, Parrish E, Millikan R, Berwick M . Tandem BRAF mutations in primary invasive melanomas. J Invest Dermatol. 2004; 122(5):1245-50. DOI: 10.1111/j.0022-202X.2004.22523.x. View

Hughes L, Melotte V, De Schrijver J, de Maat M, Smit V, Bovee J . The CpG island methylator phenotype: what's in a name?. Cancer Res. 2013; 73(19):5858-68. DOI: 10.1158/0008-5472.CAN-12-4306. View

10.

Marsit C, Christensen B, Houseman E, Karagas M, Wrensch M, Yeh R . Epigenetic profiling reveals etiologically distinct patterns of DNA methylation in head and neck squamous cell carcinoma. Carcinogenesis. 2009; 30(3):416-22. PMC: 2650795. DOI: 10.1093/carcin/bgp006. View

11.

Rebhan M, Chalifa-Caspi V, Prilusky J, Lancet D . GeneCards: a novel functional genomics compendium with automated data mining and query reformulation support. Bioinformatics. 1998; 14(8):656-64. DOI: 10.1093/bioinformatics/14.8.656. View

12.

Hoshimoto S, Kuo C, Chong K, Takeshima T, Takei Y, Li M . AIM1 and LINE-1 epigenetic aberrations in tumor and serum relate to melanoma progression and disease outcome. J Invest Dermatol. 2012; 132(6):1689-97. PMC: 3352986. DOI: 10.1038/jid.2012.36. View

13.

Guo Lian C, Xu Y, Ceol C, Wu F, Larson A, Dresser K . Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell. 2012; 150(6):1135-46. PMC: 3770275. DOI: 10.1016/j.cell.2012.07.033. View

14.

Larson A, Dresser K, Zhan Q, Lezcano C, Woda B, Yosufi B . Loss of 5-hydroxymethylcytosine correlates with increasing morphologic dysplasia in melanocytic tumors. Mod Pathol. 2014; 27(7):936-44. PMC: 4077910. DOI: 10.1038/modpathol.2013.224. View

15.

Conway K, Edmiston S, Khondker Z, Groben P, Zhou X, Chu H . DNA-methylation profiling distinguishes malignant melanomas from benign nevi. Pigment Cell Melanoma Res. 2011; 24(2):352-60. PMC: 3073305. DOI: 10.1111/j.1755-148X.2011.00828.x. View

16.

Hou P, Liu D, Dong J, Xing M . The BRAF(V600E) causes widespread alterations in gene methylation in the genome of melanoma cells. Cell Cycle. 2011; 11(2):286-95. PMC: 3293379. DOI: 10.4161/cc.11.2.18707. View

17.

Greenberg E, Chong K, Huynh K, Tanaka R, Hoon D . Epigenetic biomarkers in skin cancer. Cancer Lett. 2012; 342(2):170-7. PMC: 3391356. DOI: 10.1016/j.canlet.2012.01.020. View

18.

Liu D, Liu X, Xing M . Epigenetic genes regulated by the BRAFV600E signaling are associated with alterations in the methylation and expression of tumor suppressor genes and patient survival in melanoma. Biochem Biophys Res Commun. 2012; 425(1):45-50. PMC: 3454505. DOI: 10.1016/j.bbrc.2012.07.046. View

19.

Tellez C, Shen L, Estecio M, Jelinek J, Gershenwald J, Issa J . CpG island methylation profiling in human melanoma cell lines. Melanoma Res. 2009; 19(3):146-55. DOI: 10.1097/cmr.0b013e32832b274e. View

20.

Balch C, Gershenwald J, Soong S, Thompson J, Atkins M, Byrd D . Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009; 27(36):6199-206. PMC: 2793035. DOI: 10.1200/JCO.2009.23.4799. View